Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Kidney Cancer Clinical Trials

A listing of Kidney Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (98) clinical trials

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

This is a single center, randomized, placebo-controlled, single dosing schedule, double-blinded study to evaluate the effect of entinostat as compared to placebo on the electrical activity of the heart in patients with advanced solid tumors. Thirty patients will be randomized in a 1:1 ratio to receive either entinostat or placebo. ...

Phase

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

PRIMARY OBJECTIVE: To assess in a preliminary fashion the feasibility and efficacy of ibrutinib in combination with nivolumab in patients with previously-treated metastatic renal cell cancer (mRCC). SECONDARY OBJECTIVE: To evaluate the safety of the combination of ibrutinib and nivolumab in patients with previously treated mRCC.

Phase

Arginase Inhibitor CB-1158 in Patients With Solid Tumors

This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. Single Agent CB-1158: Patients with advanced/metastatic solid tumors be enrolled into escalating monotherapy dose cohorts to determine the Recommended Phase 2 Dose (RP2D) ...

Phase

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This is a Phase 1, open-label, single center, randomized study to assess the safety and tolerability of 3 different dose regimens of entinostat in combination with pembrolizumab in patients with advanced solid tumors who previously completed Study SNDX-275-0140 (NCT02897778). Up to 30 patients will be randomized in a 1:1:1 fashion ...

Phase

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

The primary object is to estimate the Objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with International Metastatic RCC Database Consortium (IMDC) intermediate and high risk, advanced Renal ...

Phase

Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma

Treatment with immune checkpoint inhibitors, such as nivolumab, may result in the generation of anti-tumor immune responses. However, the objective radiological response in advanced RCC patients was only 21.5%. Therefore, it is important to identify additional therapies that could augment the anti-tumor immune activity of checkpoint inhibitors, resulting in an ...

Phase